WO2001067890A3 - Composition and method to treat weight gain and obesity attributable to psychotropic drugs - Google Patents

Composition and method to treat weight gain and obesity attributable to psychotropic drugs Download PDF

Info

Publication number
WO2001067890A3
WO2001067890A3 PCT/US2001/006637 US0106637W WO0167890A3 WO 2001067890 A3 WO2001067890 A3 WO 2001067890A3 US 0106637 W US0106637 W US 0106637W WO 0167890 A3 WO0167890 A3 WO 0167890A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
attributable
obesity
psychotropic drugs
weight gain
Prior art date
Application number
PCT/US2001/006637
Other languages
French (fr)
Other versions
WO2001067890A2 (en
Inventor
Judith J Wurtman
Richard J Wurtman
Original Assignee
Massachusetts Inst Technology
Judith J Wurtman
Richard J Wurtman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Judith J Wurtman, Richard J Wurtman filed Critical Massachusetts Inst Technology
Priority to AU2001243369A priority Critical patent/AU2001243369A1/en
Publication of WO2001067890A2 publication Critical patent/WO2001067890A2/en
Publication of WO2001067890A3 publication Critical patent/WO2001067890A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

A composition and method of use for the prevention and/or treatment of weight problems attributed to the use of psychotropic drugs. The composition contains at least one form of carbohydrate and is substantially free of protein. In a preferred embodiment the composition is in the form of a snack food. Administration of the snack food results in an elevation of the subject's plasma Tp/Lnaa ratio, relative to the subject's pre-administration plasma Tp/Lnaa ratio. In alternative embodiments, the snack food either further contains tryptophan, 5-hydroxytryptophan, or melatonin, or is administered either after, concurrently, or before the administration of a second composition that contains either tryptophan, 5-hydroxytryptophan or melatonin.
PCT/US2001/006637 2000-03-14 2001-03-02 Composition and method to treat weight gain and obesity attributable to psychotropic drugs WO2001067890A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001243369A AU2001243369A1 (en) 2000-03-14 2001-03-02 Composition and method to treat weight gain and obesity attributable to psychotropic drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52505800A 2000-03-14 2000-03-14
US09/525,058 2000-03-14

Publications (2)

Publication Number Publication Date
WO2001067890A2 WO2001067890A2 (en) 2001-09-20
WO2001067890A3 true WO2001067890A3 (en) 2002-02-07

Family

ID=24091738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006637 WO2001067890A2 (en) 2000-03-14 2001-03-02 Composition and method to treat weight gain and obesity attributable to psychotropic drugs

Country Status (2)

Country Link
AU (1) AU2001243369A1 (en)
WO (1) WO2001067890A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004271796A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders
WO2007016950A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risk of alcohol induced neurodegenerative disease
WO2007016949A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risc of alcohol induced neuropathy
US8580750B2 (en) * 2005-07-29 2013-11-12 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
CN1299681C (en) * 2005-08-29 2007-02-14 陈彦方 Health caring formulation for treating insomnia
WO2008050344A2 (en) * 2006-10-25 2008-05-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of hepatic encephalopathy and liver cirrhosis
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20230023092A1 (en) 2019-04-17 2023-01-26 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007691A1 (en) * 1978-07-31 1980-02-06 Massachusetts Institute Of Technology Compositions for use in decreasing appetite for calories as carbohydrates
US4497800A (en) * 1982-07-06 1985-02-05 Mead Johnson & Company Stable liquid diet composition
WO1996039868A1 (en) * 1995-06-07 1996-12-19 Massachusetts Institute Of Technology Composition and methods for losing weight

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007691A1 (en) * 1978-07-31 1980-02-06 Massachusetts Institute Of Technology Compositions for use in decreasing appetite for calories as carbohydrates
US4497800A (en) * 1982-07-06 1985-02-05 Mead Johnson & Company Stable liquid diet composition
WO1996039868A1 (en) * 1995-06-07 1996-12-19 Massachusetts Institute Of Technology Composition and methods for losing weight

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOBREGA J N ET AL: "EFFECTS OF CHRONIC AMITRIPTYLINE AND DESIPRAMINE ON FOOD INTAKE AND BODY WEIGHT IN RATS", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 27, no. 1, 1987, pages 105 - 112, XP001030528, ISSN: 0091-3057 *
RUSS M J ET AL: "L TRYPTOPHAN DOES NOT AFFECT FOOD INTAKE DURING RECOVERY FROM DEPRESSION", INTERNATIONAL JOURNAL OF EATING DISORDERS, vol. 10, no. 5, 1991, pages 539 - 546, XP001030530, ISSN: 0276-3478 *

Also Published As

Publication number Publication date
AU2001243369A1 (en) 2001-09-24
WO2001067890A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
EA200401009A1 (en) PRELIMINARY GELATINIZED STARCH IN COMPOSITION WITH CONTROLLED DELIVERY
UA88270C2 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes
EP2044940A3 (en) Methods of treating patients suffering from movement disorders
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
ATE196084T1 (en) ORAL MEDICINAL PRODUCTS CONTAINING ONDASETRON
EP1806135A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
BG105534A (en) 5ht1 means and method for the treatment of migraine
WO2002089778A3 (en) Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
NO20055531L (en) Preparation for improved cognition and memory
WO2001067890A3 (en) Composition and method to treat weight gain and obesity attributable to psychotropic drugs
HK1030885A1 (en) The use of isatin and oxindole derivatives in the preparation of a medicament for use in the treatment of mycobacterial disease
WO2003079886A3 (en) Serotonin and catecholamine system segment optimization techonology
JP2004537500A5 (en)
EP0957925A4 (en) Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
MXPA05005781A (en) Combination of ibuprofen and oxycodone for acute pain relief.
AU6153400A (en) Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
HUP0203682A2 (en) Method for administering a phosphodiesterase 4 inhibitor
TR200102512T2 (en) The use of saredutan and its pharmaceutically acceptable salts for the preparation of medicinal products useful in the treatment or prevention of all mental disorders, adaptation disorders and various anxiety-depression disorders.
NO984572D0 (en) Use of 2,5-dihydroxybenzenesulfone derivatives for the manufacture of drugs intended for normalization of endothelial function, for the treatment of sexual dysfunction and vascular complications in diabetes, as well as vascular disorders of
WO2001005408A8 (en) Fat-binding polymers, optionally combined with lipase inhibitors
Prashar Current treatment strategies for obesity including Indian scenario
MXPA04001805A (en) A new extended release oral dosage form.
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP